Business Trends– category –
-
Dexcom Reaffirms CGM Benefits for All People with Diabetes, Expands to Preventive Care with Stelo App Relaunch and Nutrisense Acquisition at ADA 2026
DexCom, Inc. USA Overview Dexcom announced favorable results from the CONNECT randomized controlled trial at ADA 2026, reaffirming CGM's benefits for non-insulin using type 2 diabetes patients. The company also launched early access to i... -
Comprehensive Review Spotlights Lipid Nanoparticles as a Transformative Drug Delivery System
International Journal of Scientific Research and Technology (Int. J. Sci. R. Tech.) India Overview The International Journal of Scientific Research and Technology has published a detailed review positioning lipid nanoparticles (LNPs) as ... -
Lonza Pioneers Adaptive Manufacturing for In Vivo mRNA-LNP Therapies, Unlocking CRISPR for Rare Diseases and Cancer Immunotherapy
BioXconomy Switzerland Overview Lonza has unveiled an adaptive manufacturing platform designed to accelerate the development and production of in vivo mRNA-lipid nanoparticle (LNP) delivery systems. This breakthrough technology promises ... -
Beyond LNPs: Polymer Delivery Systems Promise Enhanced Stability, Reduced Toxicity, and Targeted Delivery for mRNA Therapeutics
MDPI Switzerland Overview Polymer-based delivery systems are rapidly emerging as a promising alternative to conventional lipid nanoparticles (LNPs) for mRNA therapeutics. While LNPs have achieved significant clinical success, particularl... -
Sana Biotechnology to Announce Q1 Financial Results and Hypoimmune Cell Therapy Pipeline Progress at June Investor Conferences
Stock Titan USA Overview Sana Biotechnology is scheduled to present its Q1 2026 financial results and recent business updates on its hypoimmune cell therapy and in vivo gene editing platforms at multiple investor conferences in June 2026... -
Kelonia Therapeutics’ BCMA-Targeted In Vivo CAR T Therapy KLN-1010 Shows Promise for Multiple Myeloma with Updated Phase 1 ASCO Data
Kelonia Therapeutics Press Release USA Overview Kelonia Therapeutics presented updated first-in-human data from its Phase 1 inMMyCAR study of KLN-1010, a BCMA-targeted in vivo CAR T-cell therapy, at the 2026 American Society of Clinical ... -
Voyager Therapeutics Receives FDA IND Clearance for VY1706, First Tau-Targeted Gene Therapy, to Begin Alzheimer’s Disease Phase 1 Trial
Cell & Gene Therapy Review USA Overview Voyager Therapeutics announced that its Investigational New Drug (IND) application for VY1706, a tau-targeted gene therapy for Alzheimer's disease, has been cleared by the FDA. VY1706 is a potent a... -
BlueRock Therapeutics Initiates Patient Enrollment for Parkinson’s Disease iPSC-Derived Cell Therapy exPDite-2 Phase 3 Trial; Long-Term Follow-Up Data Imminent
Neurology Live USA Overview BlueRock Therapeutics has initiated patient enrollment for its Phase 3 exPDite-2 clinical trial, transplanting iPSC-derived dopaminergic neurons in Parkinson's disease patients. The trial will involve approxim... -
Fujifilm Reshuffles Life Sciences Leadership and Opens New Facility to Quadruple iPSC Manufacturing Capacity
FUJIFILM Holdings America Corporation Press Release USA Overview FUJIFILM Holdings America Corporation announced a reshuffle in the leadership of its life sciences group, with Delara Motlagh appointed as President and COO of FUJIFILM Cel... -
Avaí Bio Achieves GMP Milestone for Anti-Aging Cell Therapy; Beam Therapeutics Targets Accelerated Approval for BEAM-302; Sana Partners with Mayo Clinic for Type 1 Diabetes
Newswire.ca Canada Overview Multiple biotech companies reported significant advancements: Avaí Bio completed its GMP-grade Master Cell Bank (MCB) for the α-Klotho anti-aging program, paving the way for preclinical and clinical trials. Be...
